 |
Daewoong Pharmaceutical. (Photo= Daewoong Pharmaceutical) |
[Alpha Biz= Reporter Paul Lee] Daewoong Pharmaceutical announced on the 11th that it received a total of 931 billion won in orders, more than nine times the target amount, from its demand forecast for unguaranteed corporate bonds, and issued an increase of 195 billion won.
Prior to the issuance of corporate bonds, the company conducted a demand forecast for 100 billion won in unguaranteed corporate bonds on the 2nd. A total of 931 billion won worth of orders came in, with a large amount of 378 billion won to raise 40 billion won for two years and 553 billion won to raise 60 billion won for three years. In other words, the company has secured more than nine times the target amount just for forecasting demand.
Following the demand forecast, Daewoong Pharmaceutical issued twice as much as its original target of 100 billion won.
Daewoong Pharmaceutical received a credit rating of A + (stable), but the assessment of the capital market received when issuing actual unguaranteed corporate bonds is similar to that of the blue-chip credit rating AA-.
Alphabiz Reporter Kim SangJin(hoondork1977@alphabiz.co.kr)
